Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BHP Billiton Limited (BHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BHP Billiton Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while BHP Billiton Limited trades at $81.24 (market cap $204.10B). The key difference: BHP Billiton Limited is far larger — about 5.1× Alnylam Pharmaceuticals, Inc.'s market cap, and BHP Billiton Limited pays a 3.26% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BHP | |
|---|---|---|
Market Cap | $39.89B | $204.10B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $93.15 |
52-Week Low | $278.09 | $50.37 |
Enterprise Value | $38.15B | $218.31B |
Dividend Yield | — | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BHP trades at $81.68, up 2.21% today, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $2.24, missing the $2.41 estimate, but beat in Q2 2025. Recent news highlights a potential strike at Port Hedland threatening daily revenue and a $2.3 billion writedown at the Jansen potash project due to cost overruns. Revenue for 2024 was $55.66 billion with a net income margin of 18.97%, while the P/E ratio stands at 20.29.
The outlook is mixed; strong profitability and cash flow support value, but operational disruptions and project cost increases pose near-term risks. Analyst consensus is cautious with 64.52% hold ratings. Investors should weigh solid fundamentals against execution challenges and commodity price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
